Recursive Superintelligence raises $650M to build self-improving AI models

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched ...
Fierce Biotech

After a decade of hype, Najat Khan is bringing Recursion back down to earth

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. | Chris ...

Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

Detailed price information for Recursion Pharmaceuticals Inc Cl A (RXRX-Q) from The Globe and Mail including charting and trades.
The Next Web

A four-month-old startup just raised $650 million to build AI that improves itself

Ex-Meta and DeepMind researchers raised $650m at a $4.65bn valuation for Recursive Superintelligence, a startup betting AI can automate its own research.
FierceBiotech

Recursion's phase 2 brain disease trial yields scant evidence of efficacy

Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...
C&EN

Recursion to buy AI rival Exscientia

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...
OfficeChai

Recursive Raises $650 Million At $4.65 Billion Valuation To Create Self-Improving AI

Brand-new startups are continuing to raise massive rounds to work on new niches of AI. Recursive, a stealth-mode AI lab, has emerged ...

Recursion to Report First Quarter 2026 Business Updates and Financial Results on May 6

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2026 ...